Volume 81, Issue 1, Pages 5-6 (January 2012)

Slides:

Advertisements

Similar presentations

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages

Advertisements

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Renal manifestations in Fabry disease and therapeutic options

Volume 68, Issue 6, Pages (December 2005)

Bettina Haslinger-Löffler Kidney International

Volume 79, Issue 9, Pages (May 2011)

The Case ∣ Acute renal failure and anemia

Volume 72, Issue 1, Pages (July 2007)

Volume 93, Issue 4, Pages (April 2018)

Why Do Patients Develop Proteinuria With Sirolimus

Volume 80, Issue 10, Pages (November 2011)

Volume 77, Issue 1, Pages 6-8 (January 2010)

Treatment of Alport syndrome: beyond animal models

Burden of chronic kidney disease: North Africa

JAK/STAT signaling in renal diseases

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 71, Issue 8, Pages (April 2007)

End-stage renal disease in living kidney donors

Volume 77, Issue 1, Pages 5-6 (January 2010)

Volume 74, Issue 10, Pages (November 2008)

Volume 68, Issue 6, Pages (December 2005)

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

The new role of calcimimetics as vasculotropic agents

Volume 81, Issue 3, Pages (February 2012)

Volume 70, Issue 11, Pages (December 2006)

Volume 74, Issue 5, Pages (September 2008)

Gary C.W. Chan, Sydney C.W. Tang Kidney International

Volume 73, Issue 7, Pages (April 2008)

Volume 86, Issue 2, Pages (August 2014)

Volume 87, Issue 2, Pages (February 2015)

Infected glomerulus Kidney International

Therapy of relapsing minimal-change disease in adults: a new approach?

Fructose intake as a risk factor for kidney stone disease

Volume 82, Issue 1, Pages 3-4 (July 2012)

Volume 78, Issue 8, Pages (October 2010)

Volume 74, Issue 6, Pages (September 2008)

Adenosine A2A agonists as therapy for glomerulonephritis

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 85, Issue 5, Pages (May 2014)

Volume 80, Issue 5, Pages (September 2011)

Calcium sensing in podocytes

Volume 87, Issue 1, Pages (January 2015)

Volume 85, Issue 1, Pages 3-4 (January 2014)

Nephrology Crossword: Glomerulonephritis

Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives Pierre Ronco, Christos Chatziantoniou

Unilateral renal cystic disease

Hydrogen: another gas with therapeutic potential

Volume 76, Issue 1, Pages 6-7 (July 2009)

Circadian regulation of renal function

Prehypertension: is it relevant for nephrologists?

Volume 87, Issue 5, Pages (May 2015)

Volume 73, Issue 9, Pages (May 2008)

Volume 82, Issue 9, Pages (November 2012)

Volume 73, Issue 5, Pages (March 2008)

Stephen O'Neill, Jeremy Hughes Kidney International

Does equal care give equal outcomes?

Is complement a target for therapy in renal disease?

Volume 74, Issue 9, Pages (November 2008)

Volume 75, Issue 7, Pages (April 2009)

Membranous nephropathy: recent travels and new roads ahead

Hisataka Kobayashi, Peter L. Choyke Kidney International

T cells and T-cell receptors in acute renal failure

The international realities of live donor kidney transplantation

Volume 75, Issue 8, Pages (April 2009)

Volume 86, Issue 3, Pages (September 2014)

Daniel L. Roden, Shane T. Grey Kidney International

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Volume 81, Issue 1, Pages 5-6 (January 2012) Journal Club Kidney International Volume 81, Issue 1, Pages 5-6 (January 2012) DOI: 10.1038/ki.2011.396 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure Schematic showing parabiotic pairings (top) and quantification of proliferating cells (bottom) in the young (left) and old (right) after parabiosis. DG, dentate gyrus. Kidney International 2012 81, 5-6DOI: (10.1038/ki.2011.396) Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure Activation of the EGFR pathway by HB-EGF in the glomerulus in RPGN. HB-EGF is expressed in the kidney in an anti-GBM disease model in mice. Bollée et al. now show that this molecule activates EGFR on podocytes and parietal epithelial cells to drive crescent formation during glomerulonephritis, renal failure, and the clinical features of RPGN. Blockade of the HB-EGF–EGFR axis with EGFR inhibitors or HB-EGF activity or release blockers may be a potential way of therapeutic intervention (Harris, Nat Med 2011; 17: 1188–1189). Kidney International 2012 81, 5-6DOI: (10.1038/ki.2011.396) Copyright © 2012 International Society of Nephrology Terms and Conditions